Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy

Table 2

Postoperative demographic characteristics of patients in the three groups.

Postoperative patient demographic		Control group	TACE group	Combined group	value
Edmondson grade	I	1 (2.5%)	1 (2.5%)	1 (2.5%)	0.677
	II	16 (40.0%)	18 (45.0%)	20 (50.0%)
	III	15 (37.5%)	14 (35%)	13 (32.5%)
	IV	8 (20.0%)	7 (17.5%)	6 (15.0%)
AJCC tumour stage	I	36 (90.0%)	34 (85.0%)	37 (92.5%)	0.549
	II	4 (10.0%)	6 (15.0%)	3 (7.5%)
Tumour number	1	36 (90.0%)	35 (87.5%)	37 (92.5%)	0.759
	2	4 (10.0%)	5 (12.5%)	3 (7.5%)
Maximum tumour size (cm)		4.31 ± 0.48	4.01 ± 0.67	3.84 ± 0.68	0.004
Fibrous capsule formation	Yes	4 (10.0%)	5 (12.5%)	6 (15.0%)	0.797
	No	36 (90.0%)	35 (87.5%)	34 (85.0%)
Tumour invasion in capsule	Yes	0 (0.0%)	4 (10.0%)	3 (7.5%)	0.141
	No	40 (100.0%)	36 (90.0%)	37 (92.5%)
Microvascular invasion	Yes	6 (15.0%)	8 (20.0%)	4 (10.0%)	0.459
	No	34 (85.0%)	32 (80.0%)	36 (90.0%)
Portal vein invasion	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.000
	No	40 (100.0%)	40 (100.0%)	40 (100.0%)
Serosa invasion	Yes	0 (0.0%)	1 (2.5%)	0 (0.0%)	0.368
	No	40 (100.0%)	39 (97.5%)	40 (100.0%)
Satellite nodule	Yes	4 (10.0%)	7 (17.5%)	4 (10.0%)	0.507
	No	36 (90.0%)	33 (82.5%)	36 (90.0%)
Surgical margin invasion	Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.000
	No	40 (100.0%)	40 (100.0%)	40 (100.0%)
Safety margin (cm)		2.60 ± 0.81	2.85 ± 1.05	2.68 ± 1.02	0.497
p53	Positive	16 (40.0%)	19 (47.5%)	20 (50.0%)	0.649
	Negative	24 (60.0%)	21 (52.5%)	20 (50.0%)